Artivion, Inc. (AORT) Dividend History

Artivion, Inc. (AORT) specializes in the development, manufacturing, and distribution of medical devices and tissue products for cardiovascular and general surgical procedures. The company focuses on providing biologic tissue products used in heart valve replacements, vascular grafts, and other surgical interventions, emphasizing regenerative and preservation techniques.

1655 Roberts Boulevard N W, Kennesaw, GA, 30144
Phone: (770) 419-3355
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
December 18, 2015 $0.03 12/09/2015 12/11/2015
September 18, 2015 $0.03 09/09/2015 09/11/2015
June 19, 2015 $0.03 06/10/2015 06/12/2015
March 20, 2015 $0.03 03/11/2015 03/13/2015
December 19, 2014 $0.03 12/10/2014 12/12/2014
Show more

Dividends Summary

  • Artivion, Inc. has issued 14 dividend payments over the past 3 years
  • The most recent dividend was paid 3459 days ago, on December 18, 2015
  • The first recorded dividend was paid on September 21, 2012
  • The highest dividend payout was $0.03 per share
  • The average dividend over this 3 year span is $0.03 per share
  • Artivion, Inc. has increased its dividend payments by 20.00% since 2012

Company News

  • $536.73 Bn Organ Preservation Solution Market Strategies and Opportunities to 2033: New R&D Center to Revolutionize Organ Preservation Techniques and Enhance Global Healthcare Solutions

    The global organ preservation solution market is expected to grow from $273.96 million in 2023 to $536.73 million in 2033, driven by factors such as the rise in organ transplant surgeries, favorable government regulations, and the growing prevalence of chronic diseases. The report highlights key market trends, including strategic investments in R&D, partnerships, and the establishment of new research centers to drive innovation in organ preservation techniques.

    GlobeNewswire Inc.
    Featured Companies: BLFS BMY TMDX
  • Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - SNS Insider

    The global Wound Closure Market is expected to grow from $15.17 billion in 2023 to $26.63 billion by 2032, driven by increasing chronic wounds, aging population, and rising healthcare infrastructure. Sutures and hemostatic agents are the key product types, with general surgery and cardiology being the major application areas.

    GlobeNewswire Inc.
    Featured Companies: BAX BSX CAH CNMD ISRG JNJ MDT MMM SYK
  • A Glimpse Into The Expert Outlook On Artivion Through 4 Analysts

    In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Frank Takkinen Lake Street Raises Buy $30.00 $28.00 Rick Wise Stifel Raises Buy $25.00 $22.00 Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.com

    Benzinga
  • Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

    AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    Zacks Investment Research
    Featured Companies: AXGN
  • Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

    Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    Zacks Investment Research
Dividend data last updated 06/07/2025 05:43:27 UTC